Kornimate/medical-research-clean huggingface dataset:
risk stratification, early prevention and treatment strategies for arrhythmogenic cardiomyopathy

Conditions: Arrhythmogenic Cardiomyopathy

Summary: this study will include patients diagnosed with arrhythmogenic cardiomyopathy (acm) in the first affiliated hospital of xi 'an jiaotong university and other centers, and collect clinical data and biological samples of patients with different acm phenotypes. through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of acm.

this study will include patients diagnosed with arrhythmogenic cardiomyopathy (acm) in the first affiliated hospital of xi 'an jiaotong university and other centers, and collect clinical data and biological samples of patients with different acm phenotypes. through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of acm.

Eligibility criteria:
inclusion criteria: * age \>18 years old. * the diagnosis of acm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing. * patients or their families agreed to participate in the study and authorized informed consent. exclusion criteria: * incomplete clinical data. * do not agree to the inclusion or refuse to authorize the informed consent.

Keywords: arrhythmogenic cardiomyopathy prognostic factors
effect of n-acetylcystein in myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: we designed this study to evaluate the effect of n-acetylcystein on biomarkers of platelet activation , cardiac necrosis and coronary reperfusion in patients undergoing percutaneous coronary intervention.

percutaneous coronary intervention(pci) is one of the standard therapies for acute coronary syndrome. despite major advances in pci procedure, impaired myocardial perfusion frequently occurred after primary pci and resulted in a larger infarct size and increased morbidity and mortality.reperfusion injury process can be resulted in additional death of cardiomyocytes and it is suggested that oxidative stress is a contributing factor to induce reperfusion injury.during pci,trauma occurs to the arterial endothelium, causes the activation and aggregation of platelets. it is estimated that approximately 25% of patients undergoing pci have significant postprocedural creatinine kinase (ck)/creatinine kinase myocardial band (ck-mb) elevations and approximately 50% of patients have significant post-procedural troponin elevations. the most common complication of pci is a cell damage to cardiomyocyte that can be diagnosed by postprocedure elevation of cardiac markers. n-acetylcystein have several positive effect on platelet and vascular function and infarct size. this study is a randomized clinical trial (rct) evaluating the effect of n-acetylcystein on biomarkers of platelet activation and coronary reperfusion in patients undergoing percutaneous coronary intervention. double blind randomized clinical trial on 100 patients in 2 groups (intervention \& control) is conducted. patients with confirmed st-elevation myocardial infarction included in this study. patients were excluded if they had: emergency for cardiac bypass; cardiogenic shock and rescue percutaneous coronary intervention. patients in intervention group were administered 100 mg/kg iv bolus n-acetylcystein and then 480mg intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary intervention and patients in control group received standard regimens. primary outcome was platelet activation biomarkers assessment before and 24 hours after percutaneous coronary intervention and secondary outcome was effect of n-acetylcystein on ck-mb and high sensitive troponin t, 6 and 12 hours after percutaneous coronary intervention.patients were assessed for coronary blood flow after percutaneous coronary intervention with the use of timi flow and myocardial blush grade. major adverse cardiac events (mace) will be evaluated as a secondary endpoint after 30 days.

Eligibility criteria:
inclusion criteria: * myocardial infarction patients who were candidate of primary pci exclusion criteria: * rescue pci * emergency for cardiac bypass * cardiogenic shock * life expectancy less than 6 months * age less than 18 years old * uncontrolled hypertension * thrombocytopenia * malformation or aneurysm * sever chronic kidney disease * sever liver failure * major surgery within 3 months * unsatisfactory to enter the study
study on management thrombosis in greek cancer patients

Conditions: Thrombosis

Summary: study on management thrombosis in greek cancer patients

the approach that medical oncologists encounter the prospect of a coagulation event occurrence in cancer patients.

Eligibility criteria:
inclusion criteria * all patients diagnosed with histologically confirmed solid tumors that are under anticoagulation therapy, during the study timeline. * age ≥ 18 years * signed informed consent exclusion criteria * initiation of anticoagulation therapy before the initiation of the study in 2016 * age \<18 years * no signed informed consent
naltrexone implants as relapse prevention

Conditions: Opioid Dependency

Summary: the purpose of this clinical trial is to study the efficacy and safety of naltrexone implants as relapse prevention for patients that are completing treatment for opiate addiction in inpatient (or similarly controlled) settings. participants in the naltrexone experimental group are prematched in a pairwise fashion with other patients who do not want a naltrexone implant during the first six months after ending inpatient treatment, but who reiceive treatment as usual (tau) from the norwegian healthcare system. the hypotheses are that quality of life, depression, opioid use, will be significantly better in the naltrexone group compared to the non at 6-, 12-, and 18-month follow-up. we also hypothesize that the implants can prevent death from opioid overdose up to 6 months after commenced treatment.


Eligibility criteria:
inclusion criteria: * soon to complete inpatient treatment for opioid addiction * living in southern norway exclusion criteria: * psychosis / major depression, currently not treated * pregnancy * liver enzymes: asat or alat \> threefold above upper boundary * maintenance treatment with methadone or buprenorphine

Keywords: substance abuse treatment relapse prevention opioid antagonist
longitudinal geriatric assessment to optimize outcomes of older patients with muscle-invasive bladder cancer after radical cystectomy

Conditions: Urinary Bladder Cancer

Summary: this single arm pilot study will evaluate the feasibility and acceptability for perioperative comprehensive geriatric assessment (cga) and cga-directed supportive and restorative care for patients with muscle-invasive bladder cancer who are planned to undergo preoperative chemotherapy.


Eligibility criteria:
inclusion criteria: * ability of participant or legally authorized representative (lar) to understand this study, and participant or lar willingness to sign a written informed consent * males and females age ≥ 65 years * diagnosis/disease status * histologically proven muscle-invasive bladder cancer (mibc) without metastatic disease. * patients planning to undergo neoadjuvant chemotherapy and radical cystectomy for mibc. * treatment with investigational systemic therapy is permitted if participants will be receiving chemotherapy as part of their treatment plan exclusion criteria: * diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements * any other known invasive malignancy within previous 2 years with the following except: low grade prostate cancer on active surveillance, chronic lymphocytic leukemia cll on surveillance / observation, non-melanoma skin cancers
obesity, sarcopenic, risk of falls in spanish postmenopausal women

Conditions: Fall Due to Loss of Equilibrium

Summary: to analyze the effects of a pilates exercise program on obesity, sarcopenic, risk of falls and health in spanish postmenopausal women.

this is a randomized clinical trial of single-blind with 2 arms (control group and experimental group), in which a pre-treatment-postest design has been used. the study will define two groups: * a control group (cg) that will not be submitted to treatment, which will be evaluated in the pre and post phase of the study. participants assigned to this group will receive general advice on the positive effects of regular physical activity and will be given a guide to recommendations for promoting physical activity. * an experimental group (ge) that after an initial evaluation will undergo a physical training program based on pilates exercises. once the intervention is finished, it will be submitted to a final evaluation to see if there is a difference or not with the results obtained at the beginning.

Eligibility criteria:
inclusion criteria: * no menstrual activity for at least 12 months. * present obesity and / or sarcopenic. * do not participate in a weight loss program. * be able to understand the instructions, programs and protocols of this project. exclusion criteria: * contraindications for conducting physical tests. * diseases that limit the static and dynamic balance and physical activity. - * central or peripheral vestibular or nerve alterations.
sex steroids, sleep, and metabolic dysfunction in women

Conditions: Polycystic Ovary Syndrome (PCOS); Obstructive Sleep Apnea; Obesity

Summary: increased plasma triglyceride concentration is a common feature of the metabolic abnormalities associated with obesity and a major risk factor for cardiovascular disease. obesity is a major risk factor for two conditions that appear to be increasing in prevalence in women: the polycystic ovary syndrome (pcos) and sleep disordered breathing. pcos affects 5-8% of women. sleep disordered breathing affects up to 10% of women. obstructive sleep apnea (osa) is the most common cause for sleep disordered breathing and particularly prevalent in obese women with pcos (\~50%). both pcos and osa augment the increase in plasma triglyceride (tg) concentration associated with obesity, and the effects of pcos and osa on plasma tg concentration appear to be additive. the mechanisms responsible for the adverse effects on plasma tg metabolism are not known. the primary goal of this project, therefore, is to determine the mechanisms responsible for the increase in plasma tg concentration in obese women with pcos and osa. it is our general hypothesis that alterations in the hormonal milieu that are characteristic of these two conditions are, at least in part, responsible for the increase in plasma tg concentration in obese women with the conditions. furthermore, we hypothesize that the hormonal aberrations characteristic of the two conditions are particularly harmful to obese, compared with lean, women. the effects of pcos on skeletal muscle protein metabolism are also not known. however, sex hormones are thought to be important regulators of muscle protein turnover suggesting that muscle protein metabolism is likely to be affected by pcos. we will examine this by determining the effect of individual sex hormones on muscle protein metabolism and hypothesize that testosterone administration will stimulate muscle protein metabolism while estrogen and progesterone administration will inhibit muscle protein metabolism.


Eligibility criteria:
inclusion criteria: * women aged 18-75 years and men 45-75 years * healthy lean, overweight and obese women (bmi 18-40 kg/m2) and obese men (bmi 30-40 kg/m2) * obese women (bmi 30-40 kg/m2) with osa or pcos exclusion criteria: * pregnant, lactating, peri- or postmenopausal women will be excluded from the study because of potential confounding influences of these factors and potential ethical concerns (pregnant women) * women taking medications known to affect substrate metabolism and those with evidence of significant organ dysfunction (e.g. impaired glucose tolerance, diabetes mellitus, liver disease, hypo- or hyper-thyroidism) other than pcos and osa * severe hypertriglyceridemia (fasting plasma tg concentration \>400 mg/dl) * subjects with osa who have an apnea-hypopnea index (ahi) score \>30 (the total number of obstructive events divided by the total hours of sleep) will be excluded and instructed to seek medical care

Keywords: sleep apnea obese very-low density lipoprotein (vldl) metabolism isotope tracer women
percutaneous microelectrolysis (mep) versus ischemic compression in miofascial trigger points

Conditions: Myofascial Trigger Point Pain

Summary: the percutaneous microelectrolysis ® (mep®) is a technique that employs a galvanic current up to 990 ua, which is applied percutaneously with an acupuncture needle connected to the cathode. although it is used in tendinopathies, trigger points and muscle injuries, among other conditions, its bases are mostly empirical and there is lack of evidence. ischemic compression is a manual therapy that is usually applied in muscle pain. myofascial pain syndrome (mps) usually presents painful myofascial trigger points (mtrps). one methodology used to quantify the pain in mps is the algometry, which measures the pressure pain threshold (ppt). the aim of this study was to compare the effects of mep® with ischemic compression on mtrps with algometry.


Eligibility criteria:
inclusion criteria: * healthy volunteers * between 18 to 30 years old. * who referred mtrp in the upper trapezious. * ppt equal or less than 3 kgf/cm2 exclusion criteria: * being pregnant. * taking analgesic medication at least 24 hours before the intervention. * being in physical therapy treatment. * needle phobia.

Keywords: galvanic current electrolysis myofascial trigger point percutaneous microelectrolysis dry needling ischemic compression
metronomic chemotherapy based on adaptative bio-mathematical model of oral vinorelbine in patients with nsclc or mpm

Conditions: Non Small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma (MPM)

Summary: background: metronomic oral vinorelbine has efficacy in metastatic nsclc and malignant pleural mesothelioma, but all the studies published thus far were based upon a variety of empirical and possibly suboptimal schedules, with inconsistent results. mathematical modeling showed by simulation that a new metronomic protocol could lead to a better safety and efficacy profile. design: this phase ia/ib trial was designed to confirm safety (phase ia) and evaluate efficacy (phase ib) of a new metronomic oral vinorelbine schedule. patient with metastatic nsclc or malignant pleural mesothelioma, after failure of standard treatments, ecog 0-2 and an adequate organ functions, will be eligible. our mathematical pk-pd model suggested an alternative weekly d1, d2 and d4 innovative schedule (named vinorelbine theoretical protocol) with a dynamic intake of 60, 30 and 60 mg, respectively. trial recruitment is two-staged as 12 patients are planned to participate in the phase ia, to confirm safety and consolidate the calibration of the average parameters of the model. depending the phase ia result, and after favorable decision of a consultative committee, the extension phase (phase ib) will be an efficacy study and will include a number of 20 patients receiving the optimal vinorelbine theoretical protocol. the primary endpoint is the tolerance (assessed by ctc v4.0) for the phase ia and the objective response according to recist 1.1 for the phase ib. an ancillary study on circulating angiogenesis biomarkers will be a subproject of the trial. discussion: this ongoing trial is the first to prospectively test a mathematical optimized schedule in metronomic chemotherapy. as such, this trial can be considered as a proof-of-concept study demonstrating the feasibility to run a computational-driven protocol to ensure an optimal efficacy/toxicity balance in patients with cancer.


Eligibility criteria:
inclusion criteria: * patients (male or female) ≥ 18 years of age. * patients with histologically documented, locally advanced or recurrent (stage iiib) or metastatic (stage iv) non-small cell lung cancer or malignant pleural mesothelioma, for which no standard exits. * presence of at least one measurable lesion according to recist v.1.1 for nsclc and modified recist 1.1 for mpm * ecog performance status ≤2 exclusion criteria: * ecog performance status \>2 * patients with significant or uncontrolled cardiovascular disease (eg, congestive heart failure, angor, arrhythmia) within 6 months of starting study treatment * any neurological or psychiatric condition interfering with the understanding of study * infectious condition uncontrolled * any other medical condition that would jeopardize the subject participation
molecular signature for breast cancer

Conditions: Breast Cancer

Summary: the main objective of this study is to evaluate and compare the diagnostic performance of a diagnostic assistance tool for analysis of 5 prognostic and predictive markers of breast cancer (her2, ki67 index, mitoses, estrogen hormone receptor, hormone progesteron receptors hormone of progesteronereceptor) integrating an automatic analysis algorithm compared to a reference (gold standard defined as the rereading by at least two different anatomopathologists according to the standard method of care) in order to show the non-inferiority of the automatic analysis algorithm compared to this gold standard.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * understanding french * with symptoms of breast cancer that required a biopsy (microbiopsy or macrobiopsy or surgical biopsy) and pathological examination diagnosing breast cancer * first diagnosis of invasive breast cancercarcinoma * affiliated to a social security system * agreeing to participate in the study exclusion criteria: * refusal to participate in the study * not affiliated to the social security system * minor or under legal protection * patient with a history of breast cancer * patient previously treated for breast cancer * patient who has relapsed from breast cancer treatment * non ductal or non lobular invasive breast cancer carcinoma
advanced coronary plaque morphology assessment using photon-counting detection and invasive coronary imaging

Conditions: Coronary Artery Disease; Coronary Disease; PCI; Stent Restenosis

Summary: this clinical trial aims to compare non-invasive photon-counting detector computed tomography (pcd-ct) with invasive intravascular imaging (ivi) for post-interventional follow-up in patients with coronary artery disease (cad). participants will undergo post-interventional follow-up using both pcd-ct and coronary angiography with ivi. researchers will test qualitative and quantitative pcd-ct results for non-inferiority to ivi regarding stent evaluation and detection of in-stent restenosis and plaque morphology.


Eligibility criteria:
inclusion criteria: * signed written informed consent * des in proximal coronary vessel segments exclusion criteria: - any conditions that may interfere with the safety or efficacy of ccta
evaluation of the dpp ii assay in laos

Conditions: Acute Febrile Illness

Summary: fever is the most frequent symptom in patients seeking care globally. several causative agents of febrile illness have been described with a high prevalence in south east asia. they include malaria, dengue, rickettsia, leptospira and burkholderia species. since their introduction in the market, rapid diagnostic tests for malaria have driven patient management and care. malaria negative cases are commonly treated with antibiotics without confirmation of bacteraemia. this can be explained by conventional laboratory diagnostic tests such as blood culture that usually require a skilled staff and appropriate facilities. several rapid diagnostic tests (rdts) are currently in the market but only limited data on their performance are available, rendering them unsuitable to replace laboratory conventional tests. in addition, rdts have been developed for single disease diagnosis and remain costly for low and middle income countries (lmic). chembio, in collaboration with find (foundation for innovative new diagnostics) and moru (mahidol oxford tropical medicine research unit), has developed a multiplex lateral flow immunoassay (dpp® fever panel ii assay) that is able to detect serum immunoglobulin m (igm) and specific microbial antigen of the most common agents of acute febrile illness (afi) in asia. the assay comes with a reader that provides results interpretation to the operator. so far, dpp ii assay performance has been estimated using a limited number of retrospective serum samples. more data are required to assess the performance of the assay using prospective serum samples. in addition, only limited data are available regarding the performance of the assay using blood samples. find will conduct a clinical trial to estimate the clinical performance of the assay in comparison to reference tests, using blood and serum samples and in intended settings of use.


Eligibility criteria:
inclusion criteria: * participants \> 12 years old enrolled in the "prospective study of the causes of fever amongst patients admitted to mahosot hospital, vientiane, lao pdr" (ui-2 study). * fever (≥ 37.5 °c) * illness duration \< 14 days * willingness to provide blood samples by venepuncture exclusion criteria: * absence of consent (and assent for children) to participate to the "prospective study of the causes of fever amongst patients admitted to mahosot hospital, vientiane, lao pdr" (ui-2 study). * non-infectious known or suspected cause of fever * no left over blood sample or insufficient volume of left over sample
expanded access program for idebenone in participants with duchenne muscular dystrophy (dmd)

Conditions: Duchenne Muscular Dystrophy

Summary: the primary objective of this expanded access program is to provide idebenone as a treatment for eligible participants with duchenne muscular dystrophy before it is commercially available in the united states (u.s.) for the indication of dmd.


Eligibility criteria:
inclusion criteria: * documented diagnosis of dmd (severe dystrophinopathy) and clinical features consistent of typical dmd at diagnosis (i.e., documented delayed motor skills and muscle weakness by age 5 years) and who in the opinion of the treating physician would benefit from treatment with idebenone. dmd should be confirmed by mutation analysis in the dystrophin gene or by substantially reduced levels of dystrophin protein (i.e., absent or \<5% of normal) on western blot or immunostaining. * minimum 8 years old at prescreening. * pef or fvc ≤80% and \>25% of predicted value based on most recent assessment noted in the patient's medical record and subsequently confirmed at the enrollment visit. * able to understand program requirements and swallow program medication. * signed and dated informed consent form (to be obtained at the enrollment visit from patient or parent/legal guardian (if applicable) prior to performing any program-specific procedures and dispensing idebenone to the patient). exclusion criteria: * eligible for and able to participate in an ongoing clinical trial of idebenone. * is at high-risk of a fatal outcome from lung infection and/or advanced cardiomyopathy in the opinion of the treating physician. * known moderate or severe impairment of hepatic function or severe impairment of renal function. * prior or ongoing medical condition or laboratory abnormality which in the treating physician's opinion may put the patient at significant risk or may interfere significantly with the patient's participation in the program. * abuse of drugs or alcohol, which in treating physician's opinion would interfere with the compliance to treatment. * known individual hypersensitivity to idebenone or to any of the ingredients/excipients of the program medication.

Keywords: idebenone, dmd, duchenne